Katelin Haley, DO
Family Medicine · Lewes, DENPI 1912256512
Payments from drug & device makers
Across 163 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$454
- Lilly USA, LLC$342
- Novo Nordisk$274
- AbbVie$220
- Pfizer$219
- Merck$164
- plus $883 from 21 others
What the payments were for
- Food & beverage$2,555100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 39 | $454 |
| Lilly USA, LLC | 19 | $342 |
| Novo Nordisk | 18 | $274 |
| AbbVie(2 entities) | 14 | $220 |
| Pfizer | 14 | $219 |
| Merck | 9 | $164 |
| Amarin Pharma, Inc. | 7 | $129 |
| GSK | 6 | $110 |
| Boehringer Ingelheim | 6 | $98 |
| Astellas Pharma US Inc | 3 | $57 |
| Amgen | 3 | $53 |
| Gilead | 3 | $50 |
| AstraZeneca | 3 | $47 |
| Corcept Therapeutics | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $37 |
| Beone Medicines USA, Inc. | 1 | $30 |
| Alkermes, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Medtronic | 1 | $23 |
| Abbott | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Philips North America LLC | 1 | $12 |
How this compares
$2,555 in reported general payments places this provider in the 80th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $126,835 |
| OzempicSemaglutide | 81 | $114,493 |
| FarxigaDapagliflozin Propanediol | 77 | $99,476 |
| RybelsusSemaglutide | 41 | $79,878 |
| MounjaroTirzepatide | 55 | $77,419 |
| TrulicityDulaglutide | 53 | $72,021 |
| JardianceEmpagliflozin | 56 | $71,571 |
| JanuviaSitagliptin Phosphate | 32 | $47,855 |
| XareltoRivaroxaban | 27 | $43,743 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $43,089 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $33,275 |
| Nurtec OdtRimegepant Sulfate | 19 | $29,533 |
| MyrbetriqMirabegron | 35 | $28,252 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $23,546 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $22,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $274 | $209,794133 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $219 | $163,278133 claims |
| Lilly USA, LLCMounjaro, Trulicity | $342 | $149,441108 claims |
| AstraZenecaFarxiga, Symbicort | $47 | $104,23688 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix, Arnuity Ellipta | $110 | $96,646162 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $98 | $83,38271 claims |
| MerckJanuvia, Janumet | $164 | $62,55144 claims |
| Johnson & JohnsonXarelto | $16 | $43,74327 claims |
| GileadBiktarvy | $50 | $43,08911 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $28,25235 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $24 | $17,48336 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $37 | $5,73611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 352 family medicine providers in Delaware.
Other family medicine in Lewes
- Catherine de LucaLewes$6K
- David KrasnerWilmington$110K
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- David BirchMilford$24K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Wayne TuckerBear$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.